Lucid Diagnostics, Inc. (LUCD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.82-8.44%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Revenue growth to support turnaround: FY26 rev $6.3M vs $7.4M; FY27 rev $16.7M vs $20.1M.
Lucid Diagnostics aims to convert demand into revenue despite recent declines. Analysts expect revenue to nearly double next year, from $7.4M in 2026 to $20.1M in 2027. The company recently raised capital to support growth. If it can improve execution, losses may narrow.
The company is still loss-making with negative EPS expected through 2027. Revenue declined recently and management progress on growth is mixed. The stock is down 27% from its high and faces elevated risk. Execution challenges and cash burn remain concerns.
The market expects about 92% revenue growth next year and values the stock at roughly $0.24 per share. Our view aligns with this cautious optimism but notes the risk from ongoing losses and execution uncertainty.
Breaks if: Capital runs low forcing dilutive financing or operational cutbacks
Breaks if: EPS loss worsens or fails to improve beyond -$0.24 in FY26 and -$0.17 in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
LUCD represents a speculative growth investment. The current thesis state indicates that while there is potential for growth, recent performance has not met expectations, leading to a cautious outlook.
The market appears to price in a high level of fragility due to LUCD's expensive valuation compared to peers. There is an expectations gap, suggesting that investors may anticipate better performance than what has been delivered recently.
Fundamentals are likely to remain under pressure in the near term, as there is a significant probability of missing earnings expectations. Recent earnings misses and a decline in company momentum indicate challenges in execution.
The long-term thesis hinges on management's ability to convert demand for EsoGuard into revenue and secure Medicare coverage. Additionally, the performance of sector bellwethers could influence LUCD's trajectory positively or negatively.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company is focusing on securing Medicare coverage for EsoGuard. This focus aligns with its goal of increasing test volumes. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $7.4M in FY26 or fails to grow toward $20.1M in FY27
In the next 1 to 3 years, LUCD's performance will depend on execution and sector dynamics. Not investment advice.